Argenx SE – American Depositary Shares (NASDAQ:ARGX) Shorts Decreased By 20.15%

May 16, 2018 - By Heather Owens

Argenx SE – American Depositary Shares (NASDAQ:ARGX) had a decrease of its shares shorted by 20.15%. In May was published ARGX’s total 134,300 shares shorted by FINRA. That’s 20.15% down from 168,200 shares. 1 days will cost ARGX with 117,000 average volume to restore its previous position. Float short on Argenx SE – American Depositary Shares is 0.61%.

The stock decreased 0.98% or $0.92 during the last trading session, hitting $92.51.Currently argenx SE is after 0.00% change in last May 16, 2017. ARGX has also 110,913 shares volume. ARGX underperformed by 11.55% the S&P 500.

argenx SE, a clinical-stage biopharmaceutical company, focuses on developing antibody therapies for the treatment of autoimmune diseases and cancer.The firm is valued at $2.99 billion. The companyÂ’s lead clinical stage product candidates include ARGX-113, a product in Phase 2 clinical trials for the treatment of autoimmune diseases, including myasthenia gravis and immune thrombocytopenia; and ARGX-110, which is in Phase 1/2 clinical trials for the treatment of hematological cancers, such as T-cell lymphoma, acute myeloid leukemia, and myelodysplastic syndrome.Last it reported negative earnings. It is also developing ARGX-111 to treat solid tumors with MET amplification; ARGX-109 for the treatment of rheumatoid arthritis; ARGX-112 to treat skin inflammation; ARGX-115, a cancer immunotherapy-focused product candidate; and ARGX-116 for the treatment of dyslipidemia.

A couple more argenx SE (NASDAQ:ARGX) news were published by: Globenewswire.com which released on May 09, 2018 “argenx reports first quarter 2018 financial results and provides business update”, also Globenewswire.com on April 24, 2018 published “argenx to present complete data from the Phase 2 proof-of-concept trial of efgartigimod (ARGX-113) in generalized …”, the next Benzinga.com is “The Week Ahead In Biotech: PDUFA Dates, IPOs And More” on April 20, 2018. Benzinga.com has article titled “Benzinga’s Daily Biotech Pulse: FDA Panel Nod For Akcea, Synergy’s Revenue Miss, FDA Warns E-Liquid Makers Again”.

argenx SE (NASDAQ:ARGX) Analyst Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.




Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: